解説【LBA16】Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, +everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+,HER2– aBC) previously treated with a CDK4/6 inhibitor (i): Primary results of the Phase III evERABC trial 酒井 瞳 （昭和医科大学）
解説【LBA20】Primary Results From ASCENT-03: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG)vs Chemotherapy (Chemo) in Patients (pts) With Previously Untreated Advanced Triple-NegativeBreast Cancer (TNBC) Who Are Unable to Receive PD-(L)1 Inhibitors (PD-[L]1i) 酒井 瞳 （昭和医科大学）
解説【LBA21】First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients withlocally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whomimmunotherapy was not an option: Primary results from the randomised, phase III TROPIONBreast02trial 酒井 瞳 （昭和医科大学）
